What is VIVS's earnings growth forecast for 2027-2027?
(NASDAQ: VIVS) Vivosim Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 108.49%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,398.91%.
Vivosim Labs's earnings in 2026 is -$13,843,000.
In 2027, VIVS is forecast to generate -$3,100,639 in earnings, with the lowest earnings forecast at -$2,979,045 and the highest earnings forecast at -$3,191,834.
What is VIVS's revenue growth forecast for 2027-2027?
(NASDAQ: VIVS) Vivosim Labs's forecast annual revenue growth rate of 80.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 21.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.03%.
Vivosim Labs's revenue in 2026 is $131,000.
In 2027, VIVS is forecast to generate $826,837 in revenue, with the lowest revenue forecast at $794,412 and the highest revenue forecast at $851,156.
What is VIVS's forecast return on assets (ROA) for 2027-2027?
(NASDAQ: VIVS) forecast ROA is -41.98%, which is lower than the forecast US Biotechnology industry average of -21.63%.
What is VIVS's Earnings Per Share (EPS) forecast for 2027-2027?
(NASDAQ: VIVS) Vivosim Labs's current Earnings Per Share (EPS) is -$5.35. In 2027, VIVS's EPS is forecast to hit -$0.89 (min: -$0.85, max: -$0.91).
What is VIVS's forecast return on equity (ROE) for 2027-2027?
(NASDAQ: VIVS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.